Cover Image


View/Hide Left Panel

Gugler R, Allgayer H. 1990. Effects of antacids on the clinical pharmacokinetics of drugs. An update. Clin Pharmacokinet 18:210–219.

Health Canada. 2000. Therapeutic Products Programme Guidance Document. Drug-Drug Interactions: Studies In Vitro and In Vivo. Online. Available at Accessed July 7, 2003.

Hurwitz A. 1971. The effects of antacids on gastrointestinal drug absorption. II. Effect on sulfadiazine and quinine. J Pharmacol Exp Ther 179:485–489.

Hurwitz A. 1977. Antacid therapy and drug kinetics. Clin Pharmacokinet 2:269–280.

Hurwitz A, Schlozman DL. 1974. Effects of antacids on gastrointestinal absorption of isoniazid in rat and man. Am Rev Respir Dis 109:41–47.

Hurwitz A, Sheehan MB. 1971. The effects of antacids on the absorption of orally administered pentobarbital in the rat. J Pharmacol Exp Ther 179:124–131.

Hurwitz A, Robinson RG, Vats TS, Whittier FC, Herrin WF. 1976. Effect of antacids on gastric emptying. Gastroenterology 71:268–273.

Indiana University. 2003. Drug Interactions. Defining Genetic Influences on Pharmacologic Responses. Online. Available at Accessed March 15, 2004.

Ingelman-Sundberg M. 2001. Implications of polymorphic cytochrome P450-dependent drug metabolism for drug development. Drug Metab Dispos 29:570–573.

Ingelman-Sundberg M, Oscarson M, McLellan RA. 1999. Polymorphic human cytochrome P450 enzymes: An opportunity for individualized drug treatment. Trends Pharmacol Sci 20:342–349.

Karliova M, Treichel U, Malago M, Frilling A, Gerken G, Broelsch CE. 2000. Interaction of Hypericum perforatum (St. John’s wort) with cyclosporin A metabolism in a patient after liver transplantation. J Hepatol 33:853–855.

Katzung BG. 2001. Basic and Clinical Pharmacology. 8th ed. New York: McGraw–Hill.

Kim RB. 2002. Transporters and xenobiotic disposition. Toxicology 181:291–297.

Lenoir M, Pedruzzi E, Rais S, Drieu K, Perianin A. 2002. Sensitization of human neutrophil defense activities through activation of platelet-activating factor receptors by ginkgolide B, a bioactive component of the Ginkgo biloba extract EGB 761. Biochem Pharmacol 63:1241–1249.

Li AP. 1997. Primary hepatocyte cultures as an in vitro experimental model for the evaluation of pharmacokinetic drug-drug interactions. Adv Pharmacol 43:103–130.

Markowitz JS, Donovan JL, DeVane CO, Taylor RM, Ruan Y, Wang J, Chavin KD. 2003. Effect of St. John’s wort on drug metabolism by induction of cytochrome P450 3A4 enzyme. J Am Med Assoc 290:1500–1504.

Meyer UA. 2000. Pharmacogenetics and adverse drug reactions. Lancet 356:1667–1671.

Nelson DR, Koymans L, Kamataki T, Stegeman JJ, Feyereisen R, Waxman DJ, Waterman MR, Gotoh O, Coon MJ, Estabrook RW, Gunsalus IC, Nebert DW. 1996. P450 superfamily: Update on new sequences, gene mapping, accession numbers and nomenclature. Pharmacogenetics 6:1–42.

Piscitelli SC, Burstein AH, Chaitt D, Alfaro RM, Falloon J. 2000. Indinavir concentrations and St John’s wort. Lancet 355:547–548.

Rodrigues AD. 1999. Applications of heterologous expressed and purified human drug-metabolizing enzymes: An industrial perspective. In: Woolf TF, ed. Handbook of Drug Metabolism. New York: Marcel Dekker. Pp. 279–320.

Ruschitzka F, Meier PJ, Turina M, Luscher TF, Noll G. 2000. Acute heart transplant rejection due to Saint John’s wort. Lancet 355:548–549.

Schwarz UI, Buschel B, Kirch W. 2003. Unwanted pregnancy on self-medication with St John’s wort despite hormonal contraception. Br J Clin Pharmacol 55:112–113.

The National Academies | 500 Fifth St. N.W. | Washington, D.C. 20001
Copyright © National Academy of Sciences. All rights reserved.
Terms of Use and Privacy Statement